Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06395844
Status:
RECRUITING
Last Update Posted:
2024-05-02
First Post:
2024-04-29
Brief Title:
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
Sponsor:
Anhui Provincial Cancer Hospital
Organization:
Anhui Provincial Cancer Hospital
Study Overview
Official Title:
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer A Single-arm Single-center Exploratory Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer
Detailed Description:
Peripheral blood will be collected from a vein of arm Peripheral blood mononuclear cells PBMc will be isolated and purified for NK manufacturing The addition of key metabolic molecules in the medium remodeled the metabolic network of NK cells significantly reduced the aging phenomenon of NK cells in the culture process improved the cell activity of NK cells and enhanced the cytotoxicity of NK cells After 14 days cultivation activated METR-NK will be harvested and formulated for clinical administration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None